BCR/ABL1 and BCR Are Under the Transcriptional Control of the MYC Oncogene

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2015 Jul 17

PMID 26179066

Citations 22

Authors

Nitesh Sharma

Vera Magistroni

Rocco Piazza

Stefania Citterio

Caterina Mezzatesta

Praveen Khandelwal

Alessandra Pirola

Carlo Gambacorti-Passerini

Affiliations

Soon will be listed here.

Abstract

Background: Chronic Myeloid Leukaemia (CML) is caused by the BCR/ABL1 fusion gene. Both the presence and the levels of BCR/ABL1 expression seem to be critical for CML progression from chronic phase (CP) to blast crisis (BC). After the oncogenic translocation, the BCR/ABL1 gene is under the transcriptional control of BCR promoter but the molecular mechanisms involved in the regulation of oncogene expression are mostly unknown.

Methods: A region of 1443bp of the functional BCR promoter was studied for transcription factor binding sites through in-silico analysis and Chromatin Immunoprecipitation experiments. BCR and BCR/ABL1 expression levels were analysed in CML cell lines after over-expression or silencing of MYC transcription factor. A luciferase reporter assay was used to confirm its activity on BCR promoter.

Results: In the present study we demonstrate that MYC and its partner MAX bind to the BCR promoter, leading to up-regulation of BCR and BCR/ABL1 at both transcriptional and protein levels. Accordingly, silencing of MYC expression in various BCR/ABL1 positive cell lines causes significant downregulation of BCR and BCR/ABL1, which consequently leads to decreased proliferation and induction of cell death.

Conclusions: Here we describe a regulatory pathway modulating BCR and BCR/ABL1 expression, showing that the BCR promoter is under the transcriptional control of the MYC/MAX heterodimer. Since MYC is frequently over-expressed in BC, this phenomenon could play a critical role in BCR/ABL1 up-regulation and blast aggressiveness acquired during CML evolution.

Citing Articles

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy.

Hsu M, Willimsky G, Hansmann L, Blankenstein T Front Immunol. 2025; 16:1518691.

PMID: 39931057 PMC: 11807957. DOI: 10.3389/fimmu.2025.1518691.

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism.

Leow B, Kok C, Yeung D, Hughes T, White D, Eadie L Sci Rep. 2023; 13(1):13110.

PMID: 37567965 PMC: 10421868. DOI: 10.1038/s41598-023-40279-2.

Stabilization of G-quadruplex DNA by ruthenium (II) complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation.

Sun Y, Chen X, Liao S, Liu A, Zhou H, Jiang L Genes Dis. 2023; 10(2):399-402.

PMID: 37223538 PMC: 10201667. DOI: 10.1016/j.gendis.2022.08.019.

Mellitin peptide quantification in seasonally collected crude bee venom and its anticancer effects on myelogenous K562 human leukaemia cell line.

Obeidat M, Al-Khraisat I, Jaradat D, Ghanim B, Abdallah Q, Arqoub D BMC Complement Med Ther. 2023; 23(1):132.

PMID: 37098530 PMC: 10127481. DOI: 10.1186/s12906-023-03897-x.

RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.

Masuda T, Maeda S, Shimada S, Sakuramoto N, Morita K, Koyama A Cancer Sci. 2021; 113(2):529-539.

PMID: 34902205 PMC: 8819354. DOI: 10.1111/cas.15239.

References

Xie S, Lin H, Sun T, Arlinghaus R . Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002; 21(47):7137-46. DOI: 10.1038/sj.onc.1205942. View

Mahon G, Wang Y, Korus M, Kostenko E, Cheng L, Sun T . The c-Myc Oncoprotein Interacts with Bcr. Curr Biol. 2003; 13(5):437-41. DOI: 10.1016/s0960-9822(03)00090-3. View

Li Z, Van Calcar S, Qu C, Cavenee W, Zhang M, Ren B . A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003; 100(14):8164-9. PMC: 166200. DOI: 10.1073/pnas.1332764100. View

Beillard E, Pallisgaard N, van der Velden V, Bi W, Dee R, van der Schoot E . Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003; 17(12):2474-86. DOI: 10.1038/sj.leu.2403136. View

Calabretta B, Perrotti D . The biology of CML blast crisis. Blood. 2004; 103(11):4010-22. DOI: 10.1182/blood-2003-12-4111. View

Jamieson C, Ailles L, Dylla S, Muijtjens M, Jones C, Zehnder J . Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-67. DOI: 10.1056/NEJMoa040258. View

Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo R, Croce C . Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982; 79(24):7824-7. PMC: 347441. DOI: 10.1073/pnas.79.24.7824. View

TAUB R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S . Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982; 79(24):7837-41. PMC: 347444. DOI: 10.1073/pnas.79.24.7837. View

Neel B, Jhanwar S, Chaganti R, Hayward W . Two human c-onc genes are located on the long arm of chromosome 8. Proc Natl Acad Sci U S A. 1982; 79(24):7842-6. PMC: 347445. DOI: 10.1073/pnas.79.24.7842. View

10.

Bartram C, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, BOOTSMA D . Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983; 306(5940):277-80. DOI: 10.1038/306277a0. View

11.

Blick M, Romero P, Talpaz M, Kurzrock R, Shtalrid M, Andersson B . Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987; 27(2):349-56. DOI: 10.1016/0165-4608(87)90018-5. View

12.

Zhu Q, Heisterkamp N, Groffen J . Unique organization of the human BCR gene promoter. Nucleic Acids Res. 1990; 18(23):7119-25. PMC: 332777. DOI: 10.1093/nar/18.23.7119. View

13.

Shah N, Witte O, Denny C . Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. Mol Cell Biol. 1991; 11(4):1854-60. PMC: 359860. DOI: 10.1128/mcb.11.4.1854-1860.1991. View

14.

Sawyers C, Callahan W, Witte O . Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992; 70(6):901-10. DOI: 10.1016/0092-8674(92)90241-4. View

15.

Amati B, Dalton S, Brooks M, Littlewood T, Evan G, Land H . Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992; 359(6394):423-6. DOI: 10.1038/359423a0. View

16.

Amati B, Brooks M, Levy N, Littlewood T, Evan G, Land H . Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993; 72(2):233-45. DOI: 10.1016/0092-8674(93)90663-b. View

17.

Gopal V, Kadam P, Preisler H, Hulette B, Li Y, Steele P . Abnormal regulation of the myc gene in myeloid leukemia. Med Oncol Tumor Pharmacother. 1992; 9(3):139-47. DOI: 10.1007/BF02987745. View

18.

Stewart M, Burgess G, Williamson E, Leibowitz D, Boswell H . Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia. 1995; 9(9):1499-507. View

19.

Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Greinix H . Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995; 86(6):2371-8. View

20.

Yoo Y, Bertolette 3rd D, Lee K, Turley J, Bang O, Ruscetti F . The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity. J Biol Chem. 1997; 272(14):8905-11. DOI: 10.1074/jbc.272.14.8905. View